By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immutep S.A. 

Parc Club Orsay, 2, Rue Jean

Rostand  Orsay  92296  France
Phone: n/a Fax:


Start Up

Company News
Prima Biomed (PRR.AX) Completes Immutep S.A. Acquisition 12/18/2014 11:17:15 AM
Prima Biomed (PRR.AX) To Host Conference Call & Webcast To Discuss Acquisition Of Immutep S.A. 10/22/2014 1:19:38 PM
Prima Biomed (PRR.AX) Announces Immutep S.A.'s IMP321 Patent Application Receives Australian Notice Of Allowance 10/14/2014 11:48:27 AM
Immutep S.A. Picks Up Prima Biomed (PRR.AX) For $28 Million 10/3/2014 1:03:22 PM
Prima Biomed (PRR.AX) Secures $37.4 Million To Fund Immutep S.A. Acquisition 10/2/2014 6:03:41 AM
Immutep S.A. And Eddingpharm (Cayman) Inc. Start Production Of Immufact® IMP321 At WuXi AppTec, Inc. In China 4/8/2014 1:36:01 PM
Immutep S.A. and Eddingpharm (Cayman) Inc. Sign Agreement for Development of ImmuFact® IMP321 in China 10/7/2013 9:25:53 AM
Immutep S.A. and Lonza Inc. Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact(R) IMP321 4/10/2012 11:23:20 AM
Immutep S.A. and GlaxoSmithKline (GSK) Sign Licence Agreement for IMP731, a Novel Therapeutic Antibody for the Treatment of Autoimmune Diseases 1/6/2011 11:09:35 AM
Immutep S.A. Announces Final Results in Phase I/II Chemoimmunotherapy Trial in Metastatic Breast Cancer 9/7/2010 1:54:45 PM